Amplyx Pharmaceuticals
Acquired
- Headquarters
- San Diego, California
- Employees
- 11–50
- Founded
- 2006
- Business Model
- B2B
- Website
- amplyx.com
- Total Funding
- $139.2M
- Last Round
- $90.0M Series CAug 2017
About
Amplyx Pharmaceuticals was a San Diego-based clinical-stage biopharmaceutical company founded in 2006 on a mission to save lives by developing a novel class of antifungal medicines to overcome the severe limitations of existing treatments. Its lead compound, fosmanogepix (APX001), represented a first-in-class antifungal mechanism targeting the Gwt1 enzyme. In April 2021, Amplyx was acquired by Pfizer Inc., which continued development of fosmanogepix as part of its infectious disease pipeline.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account